Astegolimab Biosimilar – Anti-IL1RL1 mAb – Research Grade

Description of Astegolimab Biosimilar - Anti-IL1RL1 mAb - Research Grade

Astegolimab Biosimilar: A Promising Antibody Targeting IL1RL1 for Therapeutic Applications

Astegolimab Biosimilar, also known as Anti-IL1RL1 mAb, is a monoclonal antibody that has shown great potential in targeting interleukin-1 receptor-like 1 (IL1RL1) for therapeutic purposes. IL1RL1 is a protein found on the surface of various immune cells and plays a crucial role in the inflammatory response. Astegolimab Biosimilar is a biosimilar version of the original Astegolimab, which has been developed as a more affordable and accessible alternative for research purposes.

Structure of Astegolimab Biosimilar

Astegolimab Biosimilar is a humanized monoclonal antibody, meaning it is derived from human cells and has been modified to reduce potential immune reactions. It is composed of two heavy chains and two light chains, connected by disulfide bonds. The antibody has a molecular weight of approximately 150 kDa and a half-life of about 21 days in humans.

The variable region of Astegolimab Biosimilar binds specifically to IL1RL1, while the constant region interacts with immune cells to initiate the desired therapeutic effect. The specific binding site of Astegolimab Biosimilar on IL1RL1 has been extensively studied and has been found to block the activation of the receptor, thus inhibiting the inflammatory response.

Mechanism of Action

Astegolimab Biosimilar works by binding to IL1RL1 and preventing its interaction with its ligand, interleukin-33 (IL-33). IL-33 is a pro-inflammatory cytokine that is released during tissue damage or infection, and it binds to IL1RL1 to activate immune cells and trigger the production of other inflammatory cytokines. By blocking this interaction, Astegolimab Biosimilar reduces the overall inflammatory response and helps to control immune-mediated diseases.

Additionally, Astegolimab Biosimilar has been shown to induce regulatory T cells (Tregs), which are crucial for maintaining immune tolerance and preventing excessive inflammation. This further contributes to the overall anti-inflammatory effect of Astegolimab Biosimilar.

Applications of Astegolimab Biosimilar

Astegolimab Biosimilar has shown promising results in preclinical studies for various immune-mediated diseases, such as asthma, atopic dermatitis, and rheumatoid arthritis. It has also been investigated as a potential treatment for inflammatory bowel disease, psoriasis, and other autoimmune disorders.

In addition to its therapeutic potential, Astegolimab Biosimilar is also being used in research to better understand the role of IL1RL1 in various diseases and to develop new treatment strategies. Its availability as a biosimilar has made it more accessible to researchers and has led to a better understanding of IL1RL1 as a therapeutic target.

Future Outlook

Astegolimab Biosimilar has shown promising results in preclinical studies and is currently undergoing clinical trials to evaluate its safety and efficacy in humans. If successful, it has the potential to become a valuable treatment option for various immune-mediated diseases, providing a more affordable and accessible alternative for patients.

Furthermore, the development of Astegolimab Biosimilar has opened up new avenues for research and has shed light on the therapeutic potential of targeting IL1RL1. It has also paved the way for the development of other biosimilars targeting different immune receptors, further expanding the options for treating immune-mediated diseases.

Conclusion

Astegolimab Biosimilar is a promising antibody that targets IL1RL1 for therapeutic purposes. Its specific binding to IL1RL1 and subsequent inhibition of the inflammatory response make it a potential treatment option for various immune-mediated diseases. Its availability as a biosimilar has also made it a

Astegolimab Biosimilar - Anti-IL1RL1 mAb binds to IL1RL1 / ST2, C-His, recombinant protein in indirect ELISA Assay

Immobilized IL1RL1 / ST2, C-His, recombinant protein (cat. No.PX-P5784) at 0.5µg/mL (100µL/well) can bind to Astegolimab Biosimilar - Anti-IL1RL1 mAb (cat. No.PX-TA1577) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450